Healthcare Industry News: AngioDynamics
News Release - November 8, 2011
AngioDynamics Expands Senior Leadership TeamALBANY, N.Y., Nov. 8, 2011 -- (Healthcare Sales & Marketing Network) -- AngioDynamics (Nasdaq:ANGO ), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, appointed Matthew Kapusta, Senior Vice President of Business Development, effective November 15, 2011, and Donna Haire, Senior Vice President of Regulatory, Quality, Clinical and Medical Affairs, effective immediately. Mr. Kapusta and Ms. Haire will report to President and CEO Joseph M. DeVivo.
"Matt and Donna are immensely talented and seasoned executives with significant experience in the global medical device industry," said Mr. DeVivo. "We look forward to their leadership, as well as the work they will do to advance the Company's growth through the expansion of our product portfolio and NanoKnife(R) System clinical program."
Mr. Kapusta, 39, has advised on more than 50 transactions valued at over $6 billion. While most recently serving as Vice President of Strategic Planning and Financial Analysis for Smith & Nephew Orthopaedics, he formed the Business Intelligence and Analytics team responsible for developing data-driven insights and understanding of business performance, such as surgeon attrition, sales force productivity and asset efficiency. Mr. Kapusta also spearheaded strategic and financial planning for Smith & Nephew's global Hips, Knees and Trauma franchises, identifying significant cost efficiencies that were reinvested to fund key strategic initiatives.
Prior to Smith & Nephew, Mr. Kapusta was a Managing Director of Healthcare Investment Banking at Collins Stewart in New York City. He also previously served as Vice President of Healthcare Mergers and Acquisitions at Wells Fargo Securities, and had similar roles at Robertson Stephens and PaineWebber.
Ms. Haire, 42, most recently served as Senior Director of Quality, Regulatory and Sustainability at Philips Healthcare subsidiary Global Diagnostic X-Ray in Hamburg, Germany. As a turn-around-leader, she increased compliance and strengthened accountability by driving culture change and the redesign of the Quality Management System. Ms. Haire was also the Imaging Systems Corporate Director of Regulatory, Quality, Clinical and Standards for Philips Healthcare for 21 sites world-wide, successfully creating and executing global regulatory and clinical strategies.
Prior to Philips, Ms. Haire was Director of Regulatory Affairs, Technical Communications and Compliance Engineering at Medtronic Emergency Response Systems in Redmond, Wash., leading the regulatory team in obtaining FDA market clearance for multiple products within six months. Previously she held leadership positions at Avery Dennison Medical and STERIS Corporation.
AngioDynamics, Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from AngioDynamics' expectations. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions, the results of on-going litigation, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to integrate purchased businesses, as well as the risk factors listed from time to time in AngioDynamics' SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2011. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.